ArticleDrug design, development and therapy2025
Model-Informed Precision Dosing of Remimazolam in General Anesthesia Patients.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Model-Informed Precision Dosing of Tacrolimus Initial Dosage Optimization in Membranous Nephropathy Patients.Drug design, development and therapy · 2026Article
- Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of remimazolam in patients under general anesthesia using a population analysis and to develop a web-based dashboard tool that directly displays the optimal dosing regimen for general anesthesia. Patients and Methods: A total of 20 patients received remimazolam for general anesthesia, during which intensive arterial blood samples and bispectral index (BIS) values were collected. A population PK/PD model was established, and goodness-of-fit and visual predictive check plots were utilized to evaluate the model's accuracy. Additionally, RxODE and Shiny in R were used to design a web-based dashboard tool to recommend optimal dosing regimens. Results: The three-compartment model with first elimination best described the PK profiles of remimazolam. PK parameters were weight-adjusted via allometric scaling. The correlation between drug exposure and the BIS was optimally characterized through an effect compartment model employing an inhibitory sigmoid Emax model. In addition, a web-based dashboard tool was created to offer initial personalized dosing strategies for general anesthesia procedures, enhanced by graphical representations of the PK/PD profiles associated with the recommended dosing regimens. Conclusion: The developed population PK/PD model effectively captured the dose-exposure-response relationship for remimazolam, allowing for the optimization of personalized dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.